Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

Beijing Children's Hospital50 enrolled

Overview

To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.

Octreotide subcutaneous injection is effective and safe in the treatment of congenital hyperinsulinemia in children with inefficacy of diazazine.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Congenital Hyperinsulinaemic Hypoglycaemia Octreotide Adverse Reaction

Interventions

Octreotide InjectionDRUG

Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine

Eligibility

Sex: ALLMin age: 1 MonthMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Consistent with the diagnosis of congenital hyperinsulinemia with ineffective diazine; With the maximum dose of diazine at 15mg/kg/d for 5 days, fasting blood glucose/postprandial blood glucose could not be stabilized at the target value of 3.3mmol/L without intravenous glucose infusion. 2. patients treated with octreotide subcutaneous injection. Exclusion Criteria: 1. Before the diagnosis of CHI and the treatment related to CHI, the child had received total pancreatectomy without octreotide 2. Secondary hypoglycemia caused by diseases other than CHI 3. Patients who refused to take octreotide due to parents or family economic reasons, but not hospital treatment factors. 4. Patients who intervene/interfere with octreotide treatment regimen for parental reasons

Locations (1)

Department of Endocrinology, Genetics, Metabolism

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

blood glucose

Maintain target blood glucose ≥3.3mmo/L

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.